Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Thomas Jefferson University
Thomas Jefferson University
West Virginia University
Mayo Clinic
SCRI Development Innovations, LLC
InSightec
H. Lee Moffitt Cancer Center and Research Institute
SCRI Development Innovations, LLC
Alliance for Clinical Trials in Oncology
International Atomic Energy Agency